ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Idenix: 89% of Patients in Hep C Trial Arm Achieved Viral Suppression

By Ben Fox Rubin Biopharmaceutical firm Idenix Pharmaceuticals Inc. (IDIX) has provided some results from an ongoing Phase 2b study of its lead hepatitis C drug, IDX184, showing positive suppression of the virus. Shares jumped 15% after hours Tuesday to $10.79, as the company's stock often moves sharply following reports related to its or its competitors' hepatitis C drugs. As of the market close, the shares were up 26% so far this year. Idenix is among a handful of companies scrabbling to develop a marketable all-oral Hepatitis C drug, with demand for the treatment expected to be worth billions of dollars a year. Gilead Sciences Inc. (GILD) is a main competitor of Idenix in the race develop such a drug; it spent $11 billion to buy Pharmasset this year, in part to obtain its lead hepatitis C drug candidate, GS-7977. In the Idenix study, Idenix used a mix of its IDX184 with older medications interferon and ribavirin. In all, 31 patients were enrolled and 18 reached extended rapid virologic response, which is when the virus becomes undetectable at four weeks of treatment and again at 12 weeks of treatment. Of those 18 patients, nine were given additional treatments for 12 more weeks. All but one of them achieved sustained virologic response, or undetectable traces of the virus, a month after treatment ended. The other nine patients and those who didn't reach extended rapid virologic response are continuing a regimen of 36 weeks of treatment. Write to Ben Fox Rubin at ben.rubin@dowjones.com

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
04/22/201417:30:11Gilead Sciences' Results Boosted by Hepatitis C Drug--2nd Update
04/20/201406:17:33MARKET SNAPSHOT: Long View On Stocks Is Best During Weak Earnings...
04/15/201413:30:03Sales of Johnson s New Hepatitis Drug Soars
04/11/201416:32:17MARKET SNAPSHOT: U.S. Stocks Extend Fall; S&P On Pace For 2...
04/10/201409:43:48Merck: Hepatitis C Drug Shows 98% Cure Rate in Mid-Stage Trial...
04/07/201409:55:50U.S. Hot Stocks: Hot Stock to Watch
04/07/201409:25:35Gilead Hepatitis C Treatment Designated for FDA Priority Review
04/02/201418:00:08Gilead Says Hepatitis C Drug's Trial in Japan Meets Endpoint
03/30/201408:46:34MARKET SNAPSHOT: Play-it-safe Stock Investors May Take Some Risk...
03/28/201419:33:49MARKET SNAPSHOT: U.S. Stocks End Week With Losses
03/28/201415:03:35MARKET SNAPSHOT: U.S. Stocks Pare Gains; Indexes Set For Weekly...
03/26/201416:30:44Merck, Glaxo Hold Off on Help With Affordable Care Act Copays
03/24/201415:29:56MARKET SNAPSHOT: U.S. Stocks Drift Lower After Weak PMI
03/21/201416:22:49U.S. Stocks Edge Lower
02/05/201409:38:47U.S. Hot Stocks: Hot Stocks to Watch
12/09/201309:37:22U.S. Hot Stocks Futures: Hot Stocks to Watch
11/15/201309:10:28Caxton Associates LP 3Q 13F: Largest Purchases
11/15/201309:10:28Caxton Associates LP 3Q 13F: Holdings As Of Sep 30 -2-
11/15/201309:10:27Caxton Associates LP 3Q 13F: Holdings As Of Sep 30
11/15/201308:50:01Viking Global Investors LP 3Q 13F: Largest Eliminations

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad